Date
HS Code
Importer
Exporter
Product Description
Country of Origin
Destination Country
Port of Loading
Port of Discharge
Weight
(unit)
Quantity
(unit)
Value
(unit)
2022-04-07
Small eye solution Myatro, B.No. HE6167, 1 bottle of 5ml/box, indicated to slow down the near -sighted development of children, active ingredients: Atropine sulphate 0.01%, NSX: Hanuchem Laboratories, Exp.dt: 11/2024, 100%new;Dung dịch nhỏ mắt Myatro, B.NO. HE6167, 1 lọ 5ml/hộp, chỉ định để làm chậm qt tiến triển cận thị ở trẻ em, hoạt chất: Atropine Sulphate 0.01%, nsx: Hanuchem Laboratories, EXP.DT: 11/2024, mới 100%
Small eye solution Myatro, B.No. HE6167, 1 bottle of 5ml/box, indicated to slow down the near -sighted development of children, active ingredients: Atropine sulphate 0.01%, NSX: Hanuchem Laboratories, Exp.dt: 11/2024, 100%new;Dung dịch nhỏ mắt Myatro, B.NO. HE6167, 1 lọ 5ml/hộp, chỉ định để làm chậm qt tiến triển cận thị ở trẻ em, hoạt chất: Atropine Sulphate 0.01%, nsx: Hanuchem Laboratories, EXP.DT: 11/2024, mới 100%
MUMBAI(EX BOMBAY)
HA NOI
***
KG
***
UNK
***
USD
2022-04-07
Myatro-XL small eye solution, B.NO. HE6168, 1 bottle of 5ml/box, indicated to slow down the near -sighted development of children, active ingredients: Atropine sulphate 0.05%, NSX: Hanuchem Laboratories, Exp.dt: 11/2024, 100%new;Dung dịch nhỏ mắt Myatro-XL, B.NO. HE6168, 1 lọ 5ml/hộp, chỉ định để làm chậm qt tiến triển cận thị ở trẻ em, hoạt chất: Atropine Sulphate 0.05%, nsx: Hanuchem Laboratories, EXP.DT: 11/2024, mới 100%
Myatro-XL small eye solution, B.NO. HE6168, 1 bottle of 5ml/box, indicated to slow down the near -sighted development of children, active ingredients: Atropine sulphate 0.05%, NSX: Hanuchem Laboratories, Exp.dt: 11/2024, 100%new;Dung dịch nhỏ mắt Myatro-XL, B.NO. HE6168, 1 lọ 5ml/hộp, chỉ định để làm chậm qt tiến triển cận thị ở trẻ em, hoạt chất: Atropine Sulphate 0.05%, nsx: Hanuchem Laboratories, EXP.DT: 11/2024, mới 100%
MUMBAI(EX BOMBAY)
HA NOI
***
KG
***
UNK
***
USD
2021-02-11
9 PALLET CONTAINING 526 CA RTONS PHARMACEUTICALS AS UNDER PRAVASTATIN SODIU M TAB 20MG 90 S NDC CODE:6 8462019690 FDA PRODUCT COD E NO.:-61 J C A 13 H. T. S NO.:3004.90.92.20 ANDA NO .:-77-987 THERAPEUTICE USE :-HYPOLIPDAEMICPOTASSIUM CL ER CAPS 10MEQ (750MG) 500 S NDC CODE:68462035705 FDA PRODUCT CODE NO.:65 R C F 14 H. T. S NO.:3004.9 0.92.90 ANDA NO.: 20 2868 T HERAPEUTICE USE: -TREATMEN T OR PREVENTION OF HYPOKAL EMIA 02 DATA LOGGERS HUM IDITY:65% SET TEMPERATURE : +20 DEGREES COMMERCIAL & CUSTOM INVOICE NO.F20087 001593 DT. 07.01.2021 F200 87001594 DT. 07.01.2021 N ET WT: 1008.367 FREIGHT PR EPAID THE TEMPERATURE TO BE SET AT 20 DEGREES CELC IUS IN ACCORDANCE W ITH SHI PPER S INSTRUCTIONS
9 PALLET CONTAINING 526 CA RTONS PHARMACEUTICALS AS UNDER PRAVASTATIN SODIU M TAB 20MG 90 S NDC CODE:6 8462019690 FDA PRODUCT COD E NO.:-61 J C A 13 H. T. S NO.:3004.90.92.20 ANDA NO .:-77-987 THERAPEUTICE USE :-HYPOLIPDAEMICPOTASSIUM CL ER CAPS 10MEQ (750MG) 500 S NDC CODE:68462035705 FDA PRODUCT CODE NO.:65 R C F 14 H. T. S NO.:3004.9 0.92.90 ANDA NO.: 20 2868 T HERAPEUTICE USE: -TREATMEN T OR PREVENTION OF HYPOKAL EMIA 02 DATA LOGGERS HUM IDITY:65% SET TEMPERATURE : +20 DEGREES COMMERCIAL & CUSTOM INVOICE NO.F20087 001593 DT. 07.01.2021 F200 87001594 DT. 07.01.2021 N ET WT: 1008.367 FREIGHT PR EPAID THE TEMPERATURE TO BE SET AT 20 DEGREES CELC IUS IN ACCORDANCE W ITH SHI PPER S INSTRUCTIONS
53313, JAWAHARLAL NEHRU
4601, NEW YORK/NEWARK AREA, NEWARK, NJ
***
KG
***
PKG
***
USD
2020-11-24
10 PALLET CONTAINING 457 C ARTONS PHARMACEUTICALS AS UNDER POTASSIUM CL ER CAPS 10MEQ (750MG) 100 S NDC C ODE:68462035701 FDA PRODUC T CODE NO.:65 R C F 14 H. T. S NO.:3004.90.92.90 AND A NO.:202868 THERAPEUTICE USE: -TREATMENT OR PREVENT ION OF HYPOKALEM
10 PALLET CONTAINING 457 C ARTONS PHARMACEUTICALS AS UNDER POTASSIUM CL ER CAPS 10MEQ (750MG) 100 S NDC C ODE:68462035701 FDA PRODUC T CODE NO.:65 R C F 14 H. T. S NO.:3004.90.92.90 AND A NO.:202868 THERAPEUTICE USE: -TREATMENT OR PREVENT ION OF HYPOKALEM
53313, JAWAHARLAL NEHRU
4601, NEW YORK/NEWARK AREA, NEWARK, NJ
***
KG
***
PKG
***
USD
2020-09-18
24 PALLETS CONTAINING 408 CARTONS PHARMACEUTICALS AS UNDER POTASSIUM CL ER CAP S 10MEQ (750MG) 100 S NDC CODE:68462035701 FDA PRODU CT CODE NO.:65 R C F 14 H. T. S NO.: 3004.90.92.90 A NDA NO.:202868 THERAPEUTIC E USE: - TREATMENT OR PREV ENTION OF HYPOKA
24 PALLETS CONTAINING 408 CARTONS PHARMACEUTICALS AS UNDER POTASSIUM CL ER CAP S 10MEQ (750MG) 100 S NDC CODE:68462035701 FDA PRODU CT CODE NO.:65 R C F 14 H. T. S NO.: 3004.90.92.90 A NDA NO.:202868 THERAPEUTIC E USE: - TREATMENT OR PREV ENTION OF HYPOKA
53313, JAWAHARLAL NEHRU
4601, NEW YORK/NEWARK AREA, NEWARK, NJ
***
KG
***
PKG
***
USD
2020-08-06
36 PALLETS CONTAINING 823 CARTONS PHARMACEUTICALS AS UNDER POTASSIUM CL ER CAP S 10MEQ (750MG) 100 S NDC CODE:68462035701 FDA PRODU CT CODE NO.:65 R C F 14 H. T. S NO.:3004.90.92.90 AN DA NO.:202868 THERAPEUTICE USE: - TREATMENT OR PREVE NTION OF HYPOKALE
36 PALLETS CONTAINING 823 CARTONS PHARMACEUTICALS AS UNDER POTASSIUM CL ER CAP S 10MEQ (750MG) 100 S NDC CODE:68462035701 FDA PRODU CT CODE NO.:65 R C F 14 H. T. S NO.:3004.90.92.90 AN DA NO.:202868 THERAPEUTICE USE: - TREATMENT OR PREVE NTION OF HYPOKALE
53313, JAWAHARLAL NEHRU
4601, NEW YORK/NEWARK AREA, NEWARK, NJ
***
KG
***
PKG
***
USD
2020-09-26
24 PALLETS CONTAINING 457 CARTONS PHARMACEUTICALS AS UNDER POTASSIUM CL ER CAP S 10MEQ (750MG) 100 S NDC CODE:68462035701 FDA PRODU CT CODE NO.:65 R C F 14 H. T. S NO.: 3004.90.92.90 A NDA NO.:202868 THERAPEUTIC E USE: - TREATMENT OR PREV ENTION OF HYPOKA
24 PALLETS CONTAINING 457 CARTONS PHARMACEUTICALS AS UNDER POTASSIUM CL ER CAP S 10MEQ (750MG) 100 S NDC CODE:68462035701 FDA PRODU CT CODE NO.:65 R C F 14 H. T. S NO.: 3004.90.92.90 A NDA NO.:202868 THERAPEUTIC E USE: - TREATMENT OR PREV ENTION OF HYPOKA
53313, JAWAHARLAL NEHRU
4601, NEW YORK/NEWARK AREA, NEWARK, NJ
***
KG
***
PKG
***
USD
2020-10-19
10 PALLETS 581 CARTONS PHA RMACEUTICALS AS UNDER POTA SSIUM CL ER CAPS 10MEQ (75 0MG) 500 S NDC CODE:684620 35705 FDA PRODUCT CODE NO. : 65 R C F 14 H. T. S NO.: 3004.90.92.90 ANDANO.: 2 02868 THERAPEUTICE USE: - TREATMENT O R PREVENTION OF HYPOKALEMIA PO
10 PALLETS 581 CARTONS PHA RMACEUTICALS AS UNDER POTA SSIUM CL ER CAPS 10MEQ (75 0MG) 500 S NDC CODE:684620 35705 FDA PRODUCT CODE NO. : 65 R C F 14 H. T. S NO.: 3004.90.92.90 ANDANO.: 2 02868 THERAPEUTICE USE: - TREATMENT O R PREVENTION OF HYPOKALEMIA PO
53313, JAWAHARLAL NEHRU
4601, NEW YORK/NEWARK AREA, NEWARK, NJ
***
KG
***
PKG
***
USD
2021-02-11
27 PALLET CONTAINING 808 C ARTONS PHARMACEUTICALS A S UNDER NAPROXEN TABLETS 500MG 500 S NDC CODE:6846 2019005 FDA PRODUCT CODE N O.:-62 G C A 49 H. T. S NO .:3004.90.92.40 ANDA NO.:- 78-250 THERAPEUTICE USE:-A NTI-INFLAMMATORY,ANALGESIC URSODIOL TABS 500MG 100 S NDC C ODE:68462047401 FDA PRODUCT CODE NO.:63 N C A 25 H. T. S NO.:3004.49.00 .10 ANDA NO.: 90-8 01 THER APEUTICE USE: - FOR THE TR EATMENT O F PATIENTS WITH P RIMARY BILIARY CIRRHOSIS T HE TREATMENT OF PATIENTS W ITH PRIMARY BILIARY CIRRHO SIS 02 DATA LOGGERS HUMI DITY:65% S ET TEMPERATURE : +20 DEGREES COMMERCIAL & CUSTOM INVOICE NO. F2005 2004008 DT. 08.01.2021 NE T WT: 5607.01 FREIGHT PR EPAID THE TEMPE RATURE T O BE SET AT +20 DEGREE CEL CIUS IN ACCORDANCE WITH SH IPPER INSTRUCTIONS
27 PALLET CONTAINING 808 C ARTONS PHARMACEUTICALS A S UNDER NAPROXEN TABLETS 500MG 500 S NDC CODE:6846 2019005 FDA PRODUCT CODE N O.:-62 G C A 49 H. T. S NO .:3004.90.92.40 ANDA NO.:- 78-250 THERAPEUTICE USE:-A NTI-INFLAMMATORY,ANALGESIC URSODIOL TABS 500MG 100 S NDC C ODE:68462047401 FDA PRODUCT CODE NO.:63 N C A 25 H. T. S NO.:3004.49.00 .10 ANDA NO.: 90-8 01 THER APEUTICE USE: - FOR THE TR EATMENT O F PATIENTS WITH P RIMARY BILIARY CIRRHOSIS T HE TREATMENT OF PATIENTS W ITH PRIMARY BILIARY CIRRHO SIS 02 DATA LOGGERS HUMI DITY:65% S ET TEMPERATURE : +20 DEGREES COMMERCIAL & CUSTOM INVOICE NO. F2005 2004008 DT. 08.01.2021 NE T WT: 5607.01 FREIGHT PR EPAID THE TEMPE RATURE T O BE SET AT +20 DEGREE CEL CIUS IN ACCORDANCE WITH SH IPPER INSTRUCTIONS
53313, JAWAHARLAL NEHRU
4601, NEW YORK/NEWARK AREA, NEWARK, NJ
***
KG
***
PKG
***
USD
2021-01-28
13 PALLET CONTAINING 840 C ARTONS PHARMACEUTICALS A S UNDER NAPROXEN TABLETS 500MG 500 S NDC CODE:6846 2019005 FDA PRODUCT CODE N O.:-62 G C A 49 H. T. S NO .:3004.90.92.40 ANDA NO.:- 78-250 THERAPEUTICE USE:-A NTI-INFLAMMATORY,ANALGESIC TOPIRAMATE TABLETS 25MG 60 S NDCCODE:68462010860 FDA PRODUCT CODE NO.:-61 M C A 40 H. T. S NO.:3004.4 9.00.20 ANDA NO.:- 77-627 THERAPEUTICE USE:-ANTICONV ULSANT ZONISAMIDE CAPSULE S 50MG 100 S NDC CODE:6846 2012901 FDA PRODUCT CODE N O.:-61 M C E 44 H. T.S NO .3004.49.00.20 ANDA NO.:-7 7-651 THERAP EUTICE USE:-AN TISEIZURE DRUG 01 DATA LO GGERS HUMIDITY:65% SET TEM PERATURE : +20 DEGREESCO MMERCIAL & CUSTOM INVOICE NO. F2005200374 4 DT. 22.12 .2020 NET WT:2,083.02 F REIGHT PREPAID THE TEMP ERATURE TO BE SET AT +20 D E GREE CELCIUS IN ACCORDANC E WITH SHIPPER INSTRUCTION S ON BEHALF OF : GLENMARK PHARMACEUT ICALS LIMITED N AME ACCOUNT : GLENMARK PHA RMACEUTICALS LIMITED
13 PALLET CONTAINING 840 C ARTONS PHARMACEUTICALS A S UNDER NAPROXEN TABLETS 500MG 500 S NDC CODE:6846 2019005 FDA PRODUCT CODE N O.:-62 G C A 49 H. T. S NO .:3004.90.92.40 ANDA NO.:- 78-250 THERAPEUTICE USE:-A NTI-INFLAMMATORY,ANALGESIC TOPIRAMATE TABLETS 25MG 60 S NDCCODE:68462010860 FDA PRODUCT CODE NO.:-61 M C A 40 H. T. S NO.:3004.4 9.00.20 ANDA NO.:- 77-627 THERAPEUTICE USE:-ANTICONV ULSANT ZONISAMIDE CAPSULE S 50MG 100 S NDC CODE:6846 2012901 FDA PRODUCT CODE N O.:-61 M C E 44 H. T.S NO .3004.49.00.20 ANDA NO.:-7 7-651 THERAP EUTICE USE:-AN TISEIZURE DRUG 01 DATA LO GGERS HUMIDITY:65% SET TEM PERATURE : +20 DEGREESCO MMERCIAL & CUSTOM INVOICE NO. F2005200374 4 DT. 22.12 .2020 NET WT:2,083.02 F REIGHT PREPAID THE TEMP ERATURE TO BE SET AT +20 D E GREE CELCIUS IN ACCORDANC E WITH SHIPPER INSTRUCTION S ON BEHALF OF : GLENMARK PHARMACEUT ICALS LIMITED N AME ACCOUNT : GLENMARK PHA RMACEUTICALS LIMITED
53313, JAWAHARLAL NEHRU
4601, NEW YORK/NEWARK AREA, NEWARK, NJ
***
KG
***
PKG
***
USD